Nuveen LLC bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 746,696 shares of the biopharmaceutical company's stock, valued at approximately $29,442,000. Nuveen LLC owned about 0.47% of TG Therapeutics as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Soleus Capital Management L.P. raised its position in shares of TG Therapeutics by 5.8% in the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock valued at $80,705,000 after purchasing an additional 146,702 shares during the period. Northern Trust Corp lifted its position in TG Therapeutics by 8.6% during the fourth quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company's stock worth $46,141,000 after purchasing an additional 120,785 shares during the period. Invesco Ltd. boosted its position in shares of TG Therapeutics by 30.2% during the 1st quarter. Invesco Ltd. now owns 1,210,842 shares of the biopharmaceutical company's stock worth $47,744,000 after acquiring an additional 281,099 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of TG Therapeutics by 1.3% in the 1st quarter. Principal Financial Group Inc. now owns 841,011 shares of the biopharmaceutical company's stock valued at $33,161,000 after purchasing an additional 10,827 shares in the last quarter. Finally, Braun Stacey Associates Inc. raised its stake in TG Therapeutics by 13.5% during the first quarter. Braun Stacey Associates Inc. now owns 502,650 shares of the biopharmaceutical company's stock worth $19,819,000 after acquiring an additional 59,845 shares in the last quarter. Institutional investors own 58.58% of the company's stock.
TG Therapeutics Stock Performance
Shares of TG Therapeutics stock traded up $0.3290 during mid-day trading on Friday, hitting $29.0990. 447,085 shares of the stock were exchanged, compared to its average volume of 2,480,795. The company has a 50-day simple moving average of $34.23 and a 200 day simple moving average of $35.71. The company has a market capitalization of $4.62 billion, a P/E ratio of 78.62 and a beta of 1.95. TG Therapeutics, Inc. has a 12 month low of $21.11 and a 12 month high of $46.48. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company had revenue of $141.15 million for the quarter, compared to the consensus estimate of $147.76 million. During the same quarter in the previous year, the company posted $0.04 EPS. TG Therapeutics's quarterly revenue was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.
Insider Buying and Selling
In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the transaction, the director owned 228,816 shares in the company, valued at $8,452,463.04. This trade represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.64% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a "hold" rating and set a $37.00 price target for the company in a report on Thursday, July 10th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $46.25.
Check Out Our Latest Stock Analysis on TGTX
TG Therapeutics Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Read More
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
